Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates.
Carbapenem resistant Klebsiella
Ceftazidime-avibactam
Etest
OXA-232
OXA-48-like
Sensititre plate
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
17
03
2022
revised:
25
05
2022
accepted:
10
06
2022
pubmed:
18
7
2022
medline:
3
8
2022
entrez:
17
7
2022
Statut:
ppublish
Résumé
Ceftazidime-avibactam exhibits good in vitro activity against carbapenem resistant Klebsiella carrying OXA-48-like enzymes. We tested two hundred unique carbapenem resistant Klebsiella blood stream isolates (71% with single OXA-48-like carbapenemases, including OXA-48, n = 62; OXA-232, n = 57; OXA-244, n = 17; OXA-181, n = 5) that were collected as part of a multicentre study against ceftazidime-avibactam using Etest (bioMérieux, Marcyl'Étoile, France), 10/4 μg disc (Thermo Fisher) and Sensititre Gram Negative EURGNCOL Plates (Lyophilized panels, Sensititre, Thermo Fisher) with the aim of comparing the performances of the Etest and disc to that of Sensititre. Ceftazidime-avibactam MIC
Identifiants
pubmed: 35843111
pii: S0732-8893(22)00111-0
doi: 10.1016/j.diagmicrobio.2022.115745
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Carbapenems
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
115745Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Paterson reports research grants from Merck, Pfizer and Shionogi. David Paterson has received honoraria for advisory board membership from Merck, Pfizer, Shionogi, GSK, QPex, Entasis, VenatoRx, BioMerieux, and Accelerate. Dr Harris has received research grants from Sandoz, Merck/MSD and Shionogi, speaker's fees from Pfizer and honoraria for advisory board membership from Merck and Sandoz, paid to the University of Queensland. All others have no conflict of interest to declare.